A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients With Recurrent Glioblastoma Multiforme (GBM)

Trial Profile

A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients With Recurrent Glioblastoma Multiforme (GBM)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs SL 701 (Primary) ; Bevacizumab; Poly ICLC
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Stemline Therapeutics
  • Most Recent Events

    • 21 Feb 2017 according to a Stemline Therapeutics media release, this trial has been completed and patients are being followed to assess survival. Further updates from the trial are expected later this year.
    • 21 Nov 2016 Results presented at the Society for Neuro-Oncology (SNO) annual meeting 2016, according to a Stemline Therapeutics media release.
    • 21 Nov 2016 Results published in a Stemline Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top